Durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) showed moderate improvement in overall survival (OS) in patients with MSS CRC who were previously treated with chemotherapies without a significant p value (hazard ratio = 0.7, p = 0.07). The gene discussed is CTLA4; the disease is colorectal carcinoma.